Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H12O3S |
Molecular Weight | 260.308 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)=O)C1=CC=C(C=C1)C(=O)C2=CC=CS2
InChI
InChIKey=MDKGKXOCJGEUJW-UHFFFAOYSA-N
InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
Molecular Formula | C14H12O3S |
Molecular Weight | 260.308 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) |
1.1 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
8.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | PROFENAL Approved UseInhibition of miosis during intraocular surgery. Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243932 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
18.95 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243932 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
21.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243932 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
26.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3243932 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SUPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg single, oral |
unhealthy, > 18 years n = 41 Health Status: unhealthy Age Group: > 18 years Sex: M+F Population Size: 41 Sources: |
|
600 mg single, oral Highest studied dose |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
|
400 mg single, oral |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
Other AEs: Nausea, Vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 2 patients | 400 mg single, oral |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
Vomiting | 2 patients | 400 mg single, oral |
healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
likely | |||
yes [Ki 6.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 2.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Nonsteroid anti-inflammatory agents: regulators of the phagocytic secretion of lysosomal enzymes from guinea-pig neutrophils. | 1978 Nov |
|
Skin sensitizing properties of arylalcanoic acids and their analogues. | 1979 Sep |
|
Suprofen-induced transient flank pain and renal failure. | 1987 Apr 16 |
|
Suprofen-induced acute renal failure. | 1987 Dec |
|
Suprofen and renal failure. | 1987 May |
|
Effects of suprofen on the isolated perfused rat kidney. | 1992 |
|
Five cases of photocontact dermatitis due to topical ketoprofen: photopatch testing and cross-reaction study. | 2001 Feb |
|
Disposition of suprofen enantiomers in the cat. | 2001 Jul |
|
Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate. | 2001 Jul |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Photocontact dermatitis to ketoprofen. | 2001 Sep |
|
Experimental study on phototoxicity and the photosensitization potential of ketoprofen, suprofen, tiaprofenic acid and benzophenone and the photocross-reactivity in guinea pigs. | 2002 Apr |
|
Differential binding mode of diverse cyclooxygenase inhibitors. | 2002 Mar |
|
Dextrans--potential polymeric drug carriers for suprofen. | 2003 Nov |
|
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. | 2004 Aug |
|
Predicting the pharmacokinetics of acyl glucuronides and their parent compounds in disease states. | 2006 Feb |
|
Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. | 2007 Jun |
|
New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines. | 2008 Aug 15 |
|
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | 2008 Feb |
|
Enantiomeric separation of acidic compounds by nano-liquid chromatography with methylated-beta-cyclodextrin as a mobile phase additive. | 2009 May |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:15:48 GMT 2023
by
admin
on
Fri Dec 15 15:15:48 GMT 2023
|
Record UNII |
988GU2F9PE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QM01AE07
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
||
|
WHO-ATC |
M01AE07
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m10404
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUPROFEN
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
3586
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
5359
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
100000082985
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
2546
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
988GU2F9PE
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
1642507
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
7298
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
64382-06-5
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
SUPERSEDED | |||
|
10255
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
D013496
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
C66576
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
DB00870
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
40828-46-4
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
988GU2F9PE
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5045469
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
SUB10778MIG
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
303611
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
255-096-9
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL956
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY | |||
|
9362
Created by
admin on Fri Dec 15 15:15:49 GMT 2023 , Edited by admin on Fri Dec 15 15:15:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |